Grade: Pharmaceutical Grade

Factory Location: Shandong

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Monthly Production Capacity: 1kg

Contract Manufacturing: CRO,CMO

Packaging Information: 5kg/drum

Delivery Lead Time: 15days

Sample Provided: yes

Payment Terms: L/L

Introduction

Ertugliflozin is a new SGLT2 inhibitor drug jointly developed by Pfizer and Merck. In December 2017, the US FDA approved its listing, with the trade name Steglatro, which is clinically used for the treatment of adult patients with type 2 diabetes. It has not yet been marketed in China.

Function
Ertugliflozin series impurities are used for the research and inspection of related substances in the drug research of Egliflozin.